Balinatunfib (SAR441566): A Comprehensive Report on an Investigational Oral TNF-α Inhibitor

1. Introduction to Balinatunfib

Balinatunfib, also identified by its development code SAR441566, is an experimental, orally bioavailable small molecule drug.[1] It functions as a potent inhibitor of Tumor Necrosis Factor-alpha (TNF-α), a key cytokine implicated in the pathogenesis of numerous inflammatory conditions. Developed primarily by Sanofi, Balinatunfib is under investigation for the treatment of a range of chronic autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis.[1]

The development of an orally administered small molecule targeting TNF-α, such as Balinatunfib, represents a notable strategic direction in the field of immunology. Current highly effective TNF-α inhibitors are predominantly biologic agents, such as monoclonal antibodies or fusion proteins (e.g., adalimumab [16]), which necessitate parenteral administration (e.g., subcutaneous injection or intravenous infusion).[5] While these biologics have revolutionized the treatment of many autoimmune diseases, their mode of administration can be inconvenient for patients, potentially affecting long-term adherence, particularly in chronic conditions that require lifelong management. Furthermore, biologic therapies can be associated with the development of anti-drug antibodies, leading to a loss of response or hypersensitivity reactions in some patients.[4] An orally available small molecule like Balinatunfib offers the promise of improved patient convenience and potentially reduced immunogenicity, which could translate to better adherence and sustained efficacy. This approach aims to address significant unmet needs in the management of chronic inflammatory diseases by providing a more accessible and patient-friendly therapeutic option.

Balinatunfib is classified as an anti-inflammatory small molecule, with its primary therapeutic effect derived from the inhibition of TNF-α.[1] The rationale underpinning its development is to offer a novel, orally administered treatment for TNF-mediated diseases. A crucial aspect of this rationale lies in its distinct mechanism of action compared to traditional TNF-α antagonists. Instead of directly binding to and neutralizing TNF-α or blocking its receptors in a manner similar to antibodies, Balinatunfib is designed to stabilize an inactive conformational state of the soluble TNF-α trimer, thereby preventing its downstream signaling.[1] This unique approach holds the potential for a differentiated efficacy and safety profile.

The development of Balinatunfib aligns with a broader trend in pharmaceutical research towards more targeted and potentially safer oral therapies for immunological disorders. Its specific mechanism, which aims to modulate rather than broadly suppress TNF activity, is particularly noteworthy. By differentiating between soluble TNF-α (sTNF-α) and membrane-bound TNF-α (mTNF-α) signaling, and by selectively interfering with TNFR1-mediated pathways while potentially preserving TNFR2 functions, Balinatunfib embodies a sophisticated strategy to refine immunomodulation.[1] Soluble TNF-α primarily signals through TNFR1, which is largely pro-inflammatory, whereas mTNF-α can signal through both TNFR1 and TNFR2, with TNFR2 signaling sometimes associated with regulatory or protective effects.[5] This selective modulation could theoretically lead to a better therapeutic window, maintaining some beneficial TNF functions (such as aspects of host defense mediated by mTNF-α or TNFR2) while effectively dampening the pathological inflammation driven by sTNF-α interaction with TNFR1. Such an approach could minimize the risks of broad immunosuppression, particularly the increased susceptibility to infections, which is a concern with less selective TNF inhibitors.[9] If successfully demonstrated, this refined mechanism could position Balinatunfib as a next-generation oral immunomodulator with an improved risk-benefit profile for the chronic management of autoimmune diseases.

2. Chemical and Pharmaceutical Profile

Balinatunfib is a synthetic organic small molecule.

• Nomenclature:
• International Nonproprietary Name (INN): Balinatunfib.[1]
• Development Code/Synonyms: SAR441566, SAR-441566, SAR 441566.[1]
• CAS Number: 2248726-53-4.[1]
• PubChem CID: 132042903.[1]
• IUPHAR/BPS ID: 13583.[1]
• FDA UNII: PLY98MAN4C.[13]
• Chemical Structure:
• Molecular Formula: C27​H24​F2​N6​O2​.[1]
• Molar Mass: 502.526 g·mol⁻¹ (PubChem also lists 502.5 g/mol).[1]
• IUPAC Name: (1R,11R)-5-[2-(1-aminocyclobutyl)pyrimidin-5-yl]-18-(difluoromethoxy)-12-methyl-2,9,12-triazapentacyclo[9.8.1.0²,¹⁰.0³,⁸.0¹⁴,¹⁹]icosa-3(8),4,6,9,14(19),15,17-heptaen-13-one.[13] An alternative systematic name is (7R,14R)-11-[2-(1-aminocyclobutyl)pyrimidin-5-yl]-1-(difluoromethoxy)-6-methyl-6,7-dihydro-7,14-methanobenzimidazo[1,2-b]benzodiazocin-5(14H)-one.[13]
• SMILES: CN1[C@@H]2CC@HN4C2=NC5=C4C=C(C=C5)C6=CN=C(N=C6)C7(CCC7)N.[1]
• InChIKey: UROFXMLQPAUCGV-WOJBJXKFSA-N.[1]
• Physicochemical Properties [2]:
• Hydrogen Bond Acceptors: 8.
• Hydrogen Bond Donors: 1.
• Rotatable Bonds: 4.
• Topological Polar Surface Area (TPSA): 95.88 Ų.
• XLogP: Reported as 0.95 [2] and 2.7.[13] The lower value of 0.95 is more frequently cited in sources directly discussing its properties for pharmacological databases.
• Lipinski's Rules Broken: 1 (due to molecular weight slightly exceeding 500 Da). The physicochemical profile of Balinatunfib largely supports its development as an orally administered drug. While its molecular weight (approximately 502.5 g·mol⁻¹) slightly exceeds the Lipinski guideline of ≤ 500 Da, other parameters are favorable. The number of hydrogen bond donors (1) and acceptors (8) are well within the preferred limits (≤5 and ≤10, respectively). The XLogP value, an indicator of lipophilicity, is well below the Lipinski threshold of ≤5, suggesting a good balance between solubility and permeability necessary for oral absorption. Furthermore, the topological polar surface area (TPSA) of 95.88 Ų is within the range generally considered conducive to good oral bioavailability (typically < 140 Ų). Often, a minor deviation in one Lipinski parameter, such as molecular weight, is tolerated if other physicochemical properties are optimal. Thus, the overall profile of Balinatunfib is consistent with its intended oral route of administration.
• Formulation:
• Balinatunfib is administered orally. Clinical trial descriptions indicate it is formulated as tablets, with one source specifying film-coated tablets for SAR441566.[15] The drug is designed for oral bioavailability.[1]

3. Mechanism of Action

• Primary Target: Balinatunfib primarily targets soluble Tumor Necrosis Factor-alpha (sTNF-α).[1]
• Molecular Interaction: The drug directly binds to the sTNF-α trimer, which is the biologically active form of the cytokine.[1]
• Detailed Molecular Mechanism:
• Balinatunfib functions by stabilizing an asymmetrical and functionally inactive conformation of the sTNF-α trimer.[1] This induced conformational change prevents the sTNF-α trimer from effectively binding to its principal signaling receptor, Tumor Necrosis Factor Receptor 1 (TNFR1).[7]
• By disrupting the sTNF-α/TNFR1 interaction, Balinatunfib effectively inhibits the downstream pro-inflammatory signaling pathways typically activated by TNFR1, such as the Nuclear Factor kappa-B (NF-κB) and Mitogen-Activated Protein Kinase (MAPK) pathways.[9] This ultimately leads to the inhibition of TNF-α's biological functions both in vitro and in vivo.[4]
• The stabilization of an asymmetrical trimer suggests a highly specific molecular interaction. Unlike antibody-based TNF blockers that typically sequester TNF or sterically hinder receptor binding, Balinatunfib appears to exploit a precise binding pocket on the TNF-α molecule itself. This induces an allosteric inactivation, meaning it changes the protein's shape at one site to affect its function at another (the receptor-binding site). Such precision in its mode of action could be a contributing factor to its observed or intended selectivity. Small molecules often achieve high specificity through these kinds of exact interactions within well-defined binding pockets, and allosteric mechanisms can offer greater selectivity compared to competitive inhibition at an active site, as allosteric sites tend to be more unique to a particular target protein. This precise, allosteric mechanism might be key to Balinatunfib's ability to differentiate its effects on various TNF signaling pathways.
• Selectivity:
• A defining characteristic of Balinatunfib's mechanism is its proposed selective targeting of sTNF-α signaling, predominantly mediated through TNFR1. The design aims to achieve this while preserving the signaling pathways associated with mTNF-α and potentially those mediated by TNFR2.[7]
• This selectivity is hypothesized to translate into an improved safety profile, particularly by minimizing the risk of infections, which is a common concern with less selective TNF-α blockade by traditional biologic agents.[9]
• The ability to selectively inhibit sTNF-α/TNFR1 signaling while potentially sparing mTNF-α/TNFR2 pathways could offer particular advantages in the treatment of inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, for which Balinatunfib is in Phase 2 development.[1] In the context of IBD, sTNF-α/TNFR1 signaling is largely considered pathogenic, driving inflammation and contributing to mucosal damage. Conversely, mTNF-α signaling, especially through TNFR2, has been implicated in protective mechanisms such as promoting mucosal healing and supporting immune regulation. Conventional anti-TNF biologics, which block both soluble and membrane-bound TNF and their interactions with both receptors, can be highly effective but may also interfere with these potentially beneficial pathways, contributing to side effects like increased infection risk. A therapeutic agent like Balinatunfib, by selectively dampening the detrimental sTNF-α/TNFR1 pathway while potentially leaving mTNF-α/TNFR2 functions intact [7], could offer a more targeted immunomodulatory approach. This could theoretically lead to improved long-term disease control with a more favorable safety profile for IBD patients.

4. Pharmacokinetics (Human Data)

• Administration Route: Balinatunfib is administered orally.[1]
• Studies in Healthy Volunteers: Initial pharmacokinetic assessments were conducted in Phase 1 studies involving healthy male participants. These studies evaluated single ascending doses (SAD) ranging from 5 mg to 600 mg, and multiple ascending doses (MAD) with total daily doses from 100 mg to 600 mg administered for up to 14 days.[12]
• Key Pharmacokinetic Parameters [12]:
• Time to Maximum Plasma Concentration (tmax): The median tmax was observed to be between 2.5 and 5 hours post-dose.
• Terminal Half-life (t½): The mean terminal elimination half-life ranged from 22 to 30 hours.
• Time to Steady State: Steady-state plasma concentrations were achieved within 5 to 6 days of repeated dosing.
• The pharmacokinetic profile was reported to be consistent across the range of doses evaluated in both SAD and MAD cohorts. The pharmacokinetic profile of Balinatunfib, particularly its mean terminal half-life of 22-30 hours, is supportive of a once-daily oral dosing regimen. A half-life of this duration suggests that therapeutically relevant plasma concentrations can be maintained over a 24-hour period, especially once steady state is achieved (typically after 4-5 half-lives, consistent with the reported 5-6 days to reach steady state [12]). For chronic conditions such as rheumatoid arthritis or inflammatory bowel disease, which require long-term, consistent therapy, a once-daily oral dosing schedule offers significant advantages in terms of patient convenience and adherence compared to medications requiring more frequent administration or parenteral routes.

5. Preclinical Evidence

• In Vitro Activity:
• Balinatunfib (SAR441566) has demonstrated high affinity for human TNF-α. Surface Plasmon Resonance (SPR) studies determined an average dissociation constant (KD​) of 15.1 nM.[9]
• The binding kinetics are characterized by an average association rate constant (kon​) of 1,471 M⁻¹s⁻¹ and an average dissociation rate constant (koff​) of 2.19 x 10⁻⁵ s⁻¹. The notably slow off-rate suggests a stable interaction with TNF-α.[9]
• Balinatunfib effectively inhibits various functions of TNF-α in in vitro assay systems.[4]
• In Vivo Activity (Animal Models):
• The in vivo efficacy of Balinatunfib was evaluated in the murine collagen-induced arthritis (CIA) model, a well-established preclinical model for rheumatoid arthritis. Oral administration of Balinatunfib resulted in a dose-dependent inhibition of arthritis progression.[5]
• At doses of 10 mg/kg and 30 mg/kg, Balinatunfib demonstrated efficacy comparable to that of a standard anti-TNF biologic agent in the CIA model.[5]
• These studies confirmed the ability of Balinatunfib to inhibit TNF-α functions in vivo.[4] The demonstration of efficacy comparable to an established injectable anti-TNF biologic in the CIA model [5] was a pivotal preclinical finding. It provided strong evidence that an orally administered small molecule, operating through Balinatunfib's unique mechanism of action, could achieve therapeutic effects similar to those of parenteral biologics. This was crucial for justifying the progression of Balinatunfib into human clinical trials for rheumatoid arthritis and other TNF-mediated inflammatory diseases, as it suggested that the convenience of oral dosing did not necessarily compromise the potential for significant anti-inflammatory activity.

6. Clinical Development Program

Balinatunfib (SAR441566) has been investigated or is currently under investigation across a spectrum of autoimmune and inflammatory conditions, reflecting the broad role of TNF-α in these diseases. The primary indications explored include Psoriasis, Rheumatoid Arthritis (RA), Crohn's Disease (CD), and Ulcerative Colitis (UC).[1]

Table 1: Summary of Key Balinatunfib (SAR441566) Clinical Trials

Detailed Review of Clinical Trials by Indication:

• Psoriasis: Balinatunfib's development in psoriasis has involved both Phase 1b and Phase 2 investigations. The Phase 1b study (NCT05453942) was a randomized, double-blind, placebo-controlled trial designed to assess the safety, tolerability, and clinical response of a 4-week oral treatment with SAR441566 in 38 participants with mild to moderate psoriasis.10 The primary objective focused on safety and tolerability, with clinical response measured by the relative change from baseline in Total Lesion Severity Score (TLSS) as a secondary objective. This study, sponsored by Sanofi and completed in February 2023, reportedly demonstrated efficacy and confirmed that Balinatunfib was safe and well-tolerated in this patient population.9 Following this, the SPECIFIC-PSO Phase 2 trial (NCT06073119, EudraCT 2023-503911-14-00) was initiated to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe plaque psoriasis.2 This international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study enrolled 221 participants who received treatment for 12 weeks.3 The primary endpoint was the Psoriasis Area and Severity Index (PASI-75) response, a measure of at least a 75% reduction in symptoms. According to preliminary results reported by Sanofi in its Q1 2025 earnings, the SPECIFIC-PSO trial did not meet its primary endpoint for Balinatunfib as a monotherapy; the drug was statistically no better than placebo in achieving PASI-75.12 However, Sanofi noted that Balinatunfib achieved clinically relevant changes in PASI-75, with efficacy levels comparable to other oral medicines in psoriasis, and was generally well-tolerated across doses with no new safety concerns.12 Consequently, Sanofi announced a strategic shift: development of Balinatunfib as a monotherapy for psoriasis will be halted, and future efforts will focus on investigating its potential as part of combination therapies, including fixed-dose combinations, for various diseases.12 This decision to explore combinations, despite the monotherapy trial not meeting its primary statistical endpoint, suggests that the observed safety profile and degree of clinical activity are considered sufficient to warrant further investigation in a different therapeutic context. This is a common strategic adaptation in pharmaceutical development, particularly for complex autoimmune diseases where multi-target approaches are often required for optimal efficacy.
• Rheumatoid Arthritis (RA): Balinatunfib is being evaluated in a Phase 2 trial (NCT06073093) for adults with moderate-to-severe RA who have had an inadequate response to methotrexate (MTX) and are naive to biologic or targeted synthetic DMARDs.2 This international, multicenter, randomized, double-blind, placebo-controlled, 5-arm, 12-week proof-of-concept, dose-finding study aims to assess the efficacy and safety of SAR441566 when added to background MTX therapy.27 The trial, sponsored by Sanofi, planned to enroll 264 participants and is currently listed as "Not Recruiting," having previously been recruiting.27 Sanofi expects to publish data from this RA trial in the second half of 2025.12 The context for this development is that RA is often treated with combination therapies.12 An oral TNF inhibitor like Balinatunfib, particularly if it demonstrates a favorable safety profile, could be a valuable component in such combination strategies, potentially offering improved efficacy or tolerability when used with MTX or other RA treatments.
• Crohn's Disease (CD): The SPECIFI-CD trial (NCT06637631) is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy and safety of SAR441566 in adults with moderate to severe CD.1 Sponsored by Sanofi, the study is currently recruiting an estimated 260 participants.21 The trial design includes a 12-week induction period followed by a 40-week maintenance period, both double-blind. Eligible participants may then be offered a double-blind maintenance extension (DBME) for up to 52 weeks or an open-label (OL) period for up to 92 weeks.21 The primary objective is to assess the efficacy of different doses of SAR441566 compared to placebo. The study start date is listed as December 10, 2024 3, though some sources also indicated an April 7, 2025 start.15 The comprehensive, multi-stage design of this trial underscores the commitment to evaluating both short-term induction and long-term maintenance of response and safety, which are critical parameters for a chronic and relapsing condition like Crohn's disease.
• Ulcerative Colitis (UC): A Phase 2 trial (NCT06867094) is investigating the efficacy and safety of SAR441566 in adults with moderate-to-severe UC.3 This multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study, sponsored by Sanofi, is currently recruiting an estimated 204 participants.31 The study design mirrors that of the Crohn's disease trial, with a 12-week double-blind induction period followed by a 40-week double-blind maintenance period, and an optional open-label period of up to 40 weeks. The primary objective is to assess the efficacy of different doses of SAR441566 on clinical remission.31 The study started on March 28, 2025, with an estimated study completion date of May 11, 2028.31
• Other Phase 1 Studies: In addition to the indication-specific trials, other Phase 1 studies have been conducted:
• NCT05858788: A study in healthy Japanese male participants to evaluate pharmacokinetics, safety, and tolerability.[15]
• NCT05844735: A study in healthy adults to evaluate the photosafety of SAR441566.[15]
• NCT05453942: While primarily a Phase 1b proof-of-concept in psoriasis, this study also contributed to the overall safety and tolerability data in healthy adults or those with mild disease.[15]

7. Overall Efficacy and Safety Profile

• Efficacy Summary:
• The Phase 1b trial (NCT05453942) in mild-to-moderate psoriasis suggested efficacy and demonstrated safety.[9]
• The Phase 2 SPECIFIC-PSO trial (NCT06073119) in moderate-to-severe psoriasis did not meet its primary endpoint (PASI-75) for Balinatunfib as a monotherapy. However, Sanofi reported that clinically relevant changes were observed, with efficacy levels comparable to other oral psoriasis medications.[12]
• Efficacy data from the ongoing Phase 2 trials in rheumatoid arthritis, Crohn's disease, and ulcerative colitis are not yet available, with results for the RA trial anticipated in the second half of 2025.[12]
• Safety and Tolerability Summary:
• Balinatunfib has been generally well-tolerated in the completed Phase 1 and Phase 2 psoriasis trials.[9]
• No new safety concerns were identified in the SPECIFIC-PSO trial, even though the primary efficacy endpoint was not met.[12]
• In general statements regarding biologic treatments for Crohn's disease (not specific to Balinatunfib, as results are pending), most adverse events are typically mild, and such drugs are often well-tolerated.[53] The consistent reporting of Balinatunfib being "well-tolerated" and having "no new safety concerns" across its early clinical development program [9], even in the instance where a primary efficacy endpoint was not achieved (psoriasis monotherapy), is a significant positive signal. This favorable tolerability profile is likely a key factor motivating Sanofi's decision to continue the development of Balinatunfib, particularly in combination therapies and for other indications. For drugs intended for chronic autoimmune conditions, a strong long-term safety and tolerability record is paramount, often as critical as efficacy. If Balinatunfib continues to demonstrate a good safety profile, it could become a valuable therapeutic option, especially as a component in combination regimens where the toxicity profiles of individual agents can be a limiting factor. Sanofi's emphasis on the drug's safety, even when announcing the psoriasis monotherapy trial outcome [12], suggests this is perceived as a core strength of the molecule.

8. Developer and Regulatory Landscape

• Originator and Developer:
• Sanofi is the primary originator and developer of Balinatunfib (SAR441566).[1]
• UCB Biopharma SPRL is listed as a co-assignee on the key composition of matter patent (WO2016050975A1) alongside Sanofi.[2] This joint assigneeship suggests an early collaborative role or a licensing agreement during the initial discovery or development stages of Balinatunfib or its underlying chemical scaffold. UCB Biopharma has an established presence in the immunology field, with products such as Cimzia (certolizumab pegol), another TNF inhibitor.[17] Such partnerships are common in pharmaceutical development and can be crucial for leveraging complementary expertise and resources.
• Current Development Status:
• Balinatunfib is in Phase 2 clinical development for rheumatoid arthritis, Crohn's disease, and ulcerative colitis.[1]
• Development as a monotherapy for psoriasis was halted following the Phase 2 SPECIFIC-PSO trial results; Sanofi's focus for psoriasis has shifted to investigating Balinatunfib in combination therapies.[7]
• Regulatory Designations (FDA/EMA):
• The provided research materials do not mention any specific Orphan Drug, Fast Track, Breakthrough Therapy, PRIME, or other special regulatory designations granted to Balinatunfib by the FDA or EMA for the indications under investigation.[2]
• Approval Status:
• Balinatunfib is an investigational drug and has not received marketing approval from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other regulatory authorities for any indication.[1]

9. Intellectual Property

• Key Patents:
• The primary composition of matter patent covering Balinatunfib appears to be WO2016050975A1, titled "Fused pentacyclic imidazole derivatives." This international patent application was filed with a priority date of October 2, 2015, and published on April 7, 2016. The assignees listed are UCB Biopharma SPRL and Sanofi. This patent is understood to claim the chemical structure of Balinatunfib (SAR441566).[2]
• While other patents related to TNF inhibitors or specific methods of use for inflammatory conditions may exist within Sanofi's or UCB's portfolios, details beyond this core patent for Balinatunfib's chemical entity are not extensively provided in the available research snippets. For instance, [57] mentions a patent for an anti-TNFR1 antibody, which is a different modality and not directly Balinatunfib.

10. Discussion and Future Perspectives

• Therapeutic Potential:
• As an orally administered small molecule, Balinatunfib offers a significant potential advantage in patient convenience and adherence compared to the injectable anti-TNF biologic therapies that currently dominate the treatment landscape for many chronic autoimmune diseases.[1]
• Its novel and selective mechanism of action—stabilizing an inactive form of soluble TNF-α and primarily inhibiting TNFR1 signaling while potentially sparing TNFR2 and mTNF-α functions—holds the promise of a differentiated safety profile. This could translate to a reduced risk of broad immunosuppression and associated complications, such as infections, compared to less selective TNF inhibitors.[9]
• Implications of Psoriasis Trial Results:
• The outcome of the Phase 2 SPECIFIC-PSO trial (NCT06073119), where Balinatunfib monotherapy did not meet its primary efficacy endpoint in moderate-to-severe psoriasis, was a notable setback for its development as a single agent in this specific indication.[12]
• However, the observation of clinically relevant changes and a good tolerability profile has led Sanofi to pivot its strategy towards investigating Balinatunfib in combination therapies for psoriasis and other conditions.[7] This strategic shift is critical; it indicates that while Balinatunfib may lack the standalone potency required for severe psoriasis, its favorable safety and distinct mechanism of action make it an attractive candidate for enhancing or complementing other therapeutic agents. This approach is increasingly common in managing complex autoimmune diseases, where multi-targeted strategies often yield better outcomes. Sanofi's decision reflects a pragmatic approach to drug development, aiming to identify the optimal therapeutic niche for a compound that has demonstrated some biological activity and a good safety margin.
• Future Research Directions:
• The primary focus for Balinatunfib's future development will likely be on its evaluation in combination regimens across its target indications, including psoriasis, rheumatoid arthritis, and inflammatory bowel diseases.[12]
• The results from the ongoing Phase 2 trials in rheumatoid arthritis (NCT06073093), Crohn's disease (NCT06637631), and ulcerative colitis (NCT06867094) will be crucial in determining its efficacy and safety in these patient populations and informing decisions on progression to Phase 3 studies.
• Further research will be necessary to fully elucidate the long-term safety and efficacy profile of Balinatunfib, both as a monotherapy (if pursued in any context) and as part of combination treatments.

11. Conclusion

Balinatunfib (SAR441566) is an orally active, small molecule TNF-α inhibitor distinguished by a novel mechanism of action: the stabilization of an inactive, asymmetrical conformation of soluble TNF-α trimer, leading to selective inhibition of TNFR1-mediated signaling. Preclinical studies demonstrated promising anti-inflammatory activity, comparable to biologic TNF inhibitors in relevant animal models. Early human pharmacokinetic studies have established a profile consistent with once-daily oral dosing.

While the development of Balinatunfib as a monotherapy for moderate-to-severe psoriasis was halted after a Phase 2 trial did not meet its primary efficacy endpoint, the compound was generally well-tolerated and showed clinically relevant activity. This has prompted a strategic shift by Sanofi towards evaluating Balinatunfib in combination therapies for psoriasis and continued development in Phase 2 trials for rheumatoid arthritis, Crohn's disease, and ulcerative colitis.

The key potential advantages of Balinatunfib lie in its oral route of administration, offering improved patient convenience, and its potentially differentiated safety profile stemming from its selective mechanism of action. The outcomes of the ongoing Phase 2 trials in other autoimmune indications will be critical in defining the future therapeutic role of Balinatunfib. If successful, particularly in combination strategies, Balinatunfib could represent a valuable addition to the armamentarium for managing chronic inflammatory diseases.

12. References

• Vugler A, O'Connell J, Nguyen MA, Weitz D, Leeuw T, Hickford E, et al. (2022). An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis. Frontiers in Pharmacology. 13: 1037983. [1]
• Li Y, Ye R, Dai H, Lin J, Cheng Y, Zhou Y, et al. (January 2025). Exploring TNFR1: from discovery to targeted therapy development. Journal of Translational Medicine. 23 (1): 71. [1]
• Clinical trial registry entries: ClinicalTrials.gov, EU Clinical Trials Register (EudraCT). (Various snippet IDs)
• Drug information databases: PubChem [1], Guide to Pharmacology (IUPHAR/BPS) [1], AdisInsight (Springer) [3], Ozmosi Pryzm.[8]
• Company communications: Sanofi press releases and investor presentations (e.g., Q1 2025 earnings information).[3]
• Patent WO2016050975A1. De Haro Garcia T, et al. Fused pentacyclic imidazole derivatives. Assignee: UCB Biopharma SPRL, Sanofi..[2]

Works cited

1. Balinatunfib - Wikipedia, accessed May 13, 2025, https://en.wikipedia.org/wiki/Balinatunfib
2. balinatunfib | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed May 13, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=13583
3. Balinatunfib - Sanofi - AdisInsight - Springer, accessed May 13, 2025, https://adisinsight.springer.com/drugs/800064810
4. A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis, accessed May 13, 2025, https://www.sanofistudies.com/cwout/CW-V9DEXS//gb/en/listing/312883/a-study-to-evaluate-9/
5. An orally available small molecule that targets soluble ... - Frontiers, accessed May 13, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1037983/full
6. An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis - PubMed, accessed May 13, 2025, https://pubmed.ncbi.nlm.nih.gov/36467083/
7. Balinatunfib (Synonyms: SAR-441566; TNFα activity modulator 3) - MedchemExpress.com, accessed May 13, 2025, https://www.medchemexpress.com/tnf%CE%B1-activity-modulator-3.html
8. Balinatunfib Drug Profile - Ozmosi, accessed May 13, 2025, https://pryzm.ozmosi.com/product/sar-441566
9. Affinity of SAR441566 binding to human TNF. | Download Scientific ..., accessed May 13, 2025, https://www.researchgate.net/figure/Affinity-of-SAR441566-binding-to-human-TNF_tbl1_365436161
10. In vivo efficacy of SAR441566 in the CIA Model: The dose ..., accessed May 13, 2025, https://www.researchgate.net/figure/In-vivo-efficacy-of-SAR441566-in-the-CIA-Model-The-dose-dependent-in-vivo-efficacy-of_fig3_365436161
11. Exploring TNFR1: from discovery to targeted therapy development ..., accessed May 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11734553/
12. Balinatunfib - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 13, 2025, https://synapse.patsnap.com/drug/aef085ae92494db69f0d0bc862bee61b
13. Balinatunfib | C27H24F2N6O2 | CID 132042903 - PubChem, accessed May 13, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/132042903
14. balinatunfib | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed May 13, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=refs&ligandId=13583
15. Sar441566 – Application in Therapy and Current Clinical Research, accessed May 13, 2025, https://clinicaltrials.eu/inn/sar441566/
16. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial - PubMed, accessed May 13, 2025, https://pubmed.ncbi.nlm.nih.gov/16472588/
17. Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail, accessed May 13, 2025, https://www.clinicaltrialsarena.com/news/balinatunfib-sanofi-monotherapy-fail/
18. Sanofi's oral TNF asset misses mark in phase 2 psoriasis trial - Fierce Biotech, accessed May 13, 2025, https://www.fiercebiotech.com/biotech/sanofis-oral-tnf-inhibitor-misses-mark-phase-2-psoriasis-trial-prompting-focus-combos
19. BALINATUNFIB - precisionFDA, accessed May 13, 2025, https://precision.fda.gov/ginas/app/ui/substances/11378058-b47d-4792-b6a8-684383611358
20. Balinatunfib - GSRS, accessed May 13, 2025, https://gsrs.ncats.nih.gov/ginas/app/beta/substances/PLY98MAN4C
21. A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease., accessed May 13, 2025, https://ctv.veeva.com/study/a-study-to-investigate-efficacy-and-safety-of-sar441566-in-patients-with-crohns-disease
22. Allergy to ustekinumab: Validating skin tests for diagnostic and therapeutic decision-making, accessed May 13, 2025, https://pubmed.ncbi.nlm.nih.gov/40051429/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=0ZNDJPidxPs2Ab5omGs4ojdmkKuLsYmdZvu8BvoFV7w&fc=None&ff=20250323100104&v=2.18.0.post9+e462414
23. Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed, accessed May 13, 2025, https://www.sanofi.com/en/media-room/press-releases/2025/2025-04-24-05-30-00-3067075
24. Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed, accessed May 13, 2025, https://www.globenewswire.com/news-release/2025/04/24/3067075/0/en/Press-Release-Sanofi-strong-Q1-performance-and-2025-guidance-confirmed.html
25. A Study to Evaluate Efficacy and Safety of SAR441566 in Adults ..., accessed May 13, 2025, https://www.ngram.com/trials/NCT06073119
26. A Study to Investigate Safety, Tolerability and Clinical Response ..., accessed May 13, 2025, https://www.ngram.com/trials/NCT05453942
27. A Study to Evaluate SAR441566 Efficacy and Safety | Clinical ..., accessed May 13, 2025, https://www.sanofistudies.com/cwout/CW-V9DEXS//us/en/listing/312881/a-study-to-evaluate-8/
28. A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis, accessed May 13, 2025, https://trials.arthritis.org/trials/NCT06073093
29. ANZCTR search results | Australian Clinical Trials, accessed May 13, 2025, https://www.australianclinicaltrials.gov.au/anzctr-search-results?search_text=&condition_category=all&condition_code=all&recruitment_status=Recruitingðics_approval=all&page=480
30. TNFR1 - Drugs, Indications, Patents - Synapse - Patsnap Synapse, accessed May 13, 2025, https://synapse.patsnap.com/target/b1ffa8ebc6be4256872d64a7cc24cd60
31. A Study to Investigate Efficacy and Safety of SAR441566 in Patients ..., accessed May 13, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06867094/a-study-to-investigate-efficacy-and-safety-of-sar441566-in-patients-with-ulcerative-colitis?id=88&slug=inflammatory-bowel-disease
32. strong Q1 performance and 2025 guidance confirmed - Sanofi, accessed May 13, 2025, https://www.sanofi.com/assets/dotcom/pressreleases/2025/2025-04-24-05-30-00-3067075-en.pdf
33. First quarter 2025 l Sanofi, accessed May 13, 2025, https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/q1-2025-results
34. EU/3/14/1335 - orphan designation for treatment of pemphigus | European Medicines Agency (EMA), accessed May 13, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1335
35. EU Clinical Trials Register, accessed May 13, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000465-32/PT
36. EU Clinical Trials Register, accessed May 13, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005273-47/NL
37. Investor Presentations - Sanofi, accessed May 13, 2025, https://www.sanofi.com/en/investors/financial-results-and-events/investor-presentations
38. Search for eudract_number - Clinical Trials register, accessed May 13, 2025, https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number
39. EU Clinical Trials Register - Update, accessed May 13, 2025, https://www.clinicaltrialsregister.eu/
40. Search for eudract_number:2021-005086-41 - Clinical Trials register, accessed May 13, 2025, https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-005086-41
41. EU Clinical Trials Register, accessed May 13, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001240-35/DE
42. PT - EU Clinical Trials Register, accessed May 13, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003538-16/PT
43. A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis, accessed May 13, 2025, https://ctv.veeva.com/study/a-study-to-investigate-efficacy-and-safety-of-sar441566-in-patients-with-ulcerative-colitis
44. EU Clinical Trials Register, accessed May 13, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001942-20/NL
45. ClinicalTrials.gov: Home, accessed May 13, 2025, https://clinicaltrials.gov/
46. accessed January 1, 1970, https://www.centerwatch.com/clinical-trials/listings/NCT06867094/
47. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT06637631
48. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT06867094
49. accessed January 1, 1970, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=386554&isReview=true
50. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT06073093
51. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT05453942
52. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT06073119
53. The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate–Severe Crohn's Disease: A Systematic Review - PubMed Central, accessed May 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10674451/
54. FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management - PubMed, accessed May 13, 2025, https://pubmed.ncbi.nlm.nih.gov/31671561/
55. FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management - PMC - PubMed Central, accessed May 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6921037/
56. Finance Pipeline Business Appendices - Sanofi, accessed May 13, 2025, https://www.sanofi.com/assets/dotcom/content-app/events/quaterly-results/2025/2024-q4-and-full-year-2024-results/2025-01-30_Sanofi-Q4FY-2024.pdf
57. US11028178B2 - Method of treating nonalcoholic steatohepatitis by administering an antagonist human tumor necrosis factor receptor 1 (HUTNFR1) antibody - Google Patents, accessed May 13, 2025, https://patents.google.com/patent/US11028178B2/en